TRIB1 and non-small cell lung carcinoma: Wang et al. demonstrated that cisplatin treatment, but not paclitaxel and doxorubicin treatment, result in the enrichment of CSCs, conferring multidrug resistance in NSCLC cell lines by the induction of TRIB1 and HDACs [135].